Advanced search×
×
  1. Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features.

    BMC Cancer 10:227 (2010) PMID 20492682 PMCID PMC2880997

    We performed comprehensive DNA methylation profiling of CRC with the aim of characterizing CIMP subgroups. DNA methylation at 1,505 CpG sites in 807 cancer-related genes was evaluated using the Illumina GoldenGate methylation array in 28 normal colonic mucosa and 91 consecutive CRC s...
  2. Degradation of human secretory immunoglobulin A by Blastocystis.

    Parasitology Research 97(5):386 (2005) PMID 16151742

    Microbial immunoglobulin A (IgA) proteases cleave human secretory IgA, promoting the mucosal adhesion of pathogens. To investigate if the enteric protozoan Blastocystis degrades human secretory IgA, cell lysate and conditioned medium from two species were exposed to immunoglobulin A. Secretory IgA w...
  3. DNA methylation subgroups and the CpG island methylator phenotype in gastric cancer: a comprehensive profiling approach.

    BMC Gastroenterology 14(1):55 (2014) PMID 24674026 PMCID PMC3986689

    We performed comprehensive DNA methylation profiling of a well-characterised series of primary GC. The methylation status of 1,421 autosomal CpG sites located within 768 cancer-related genes was investigated using the Illumina GoldenGate Methylation Panel I assay on DNA extracted from 60 gastric tum...
  4. Impact of sample heterogeneity on methylation analysis.

    Diagnostic Molecular Pathology 19(4):243 (2010) PMID 21051995

    We analyzed 98 unselected formalin-fixed and paraffin-embedded gastric tumors and matched normal tissue samples using the Illumina GoldenGate methylation assay. Unsupervised hierarchical clustering showed 2 separate clusters with a significant difference in average tumor content levels. The probes i...
  5. MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer

    European Journal of Cancer 46(8):1456 (2010) PMID 20176475

    Aim Accumulating evidence indicates that RUNX3 is an important tumour suppressor that is inactivated in many cancer types. This study aimed to assess the role of microRNA (miRNA) in the regulation of RUNX3.